Insulet (PODD) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -6.51% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 7.96% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -2.19% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 64.73% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 30.89% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 60.12% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 29.56% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Insulet | 10.37 Bn | 9.89 Bn | 529.10 Mn | 56.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.43% |
| Dec 31, 2025 | 81.53% |
| Sep 30, 2025 | 166.12% |
| Jun 30, 2025 | 38.26% |
| Mar 31, 2025 | 8.49% |
| Dec 31, 2024 | 51.08% |
| Sep 30, 2024 | 83.22% |
| Jun 30, 2024 | 112.12% |
| Dec 31, 2023 | 100.39% |
| Sep 30, 2023 | 64.78% |
| Jun 30, 2023 | 23.77% |
| Mar 31, 2023 | 137.13% |
| Dec 31, 2022 | 50.37% |
| Sep 30, 2022 | -104.08% |
| Jun 30, 2022 | -200.00% |
| Mar 31, 2022 | 84.87% |
| Dec 31, 2021 | 43.41% |
| Sep 30, 2021 | 96.57% |
| Jun 30, 2021 | -145.43% |
| Dec 31, 2019 | 427.83% |
| Sep 30, 2019 | 143.85% |
| Jun 30, 2019 | 109.16% |
| Mar 31, 2019 | 64.55% |
| Dec 31, 2018 | 42.06% |
| Sep 30, 2018 | 55.49% |
| Jun 30, 2018 | -42.96% |
| Mar 31, 2018 | -67.45% |
| Dec 31, 2016 | 26.28% |
| Sep 30, 2016 | 85.57% |
| Jun 30, 2016 | 26.30% |
| Mar 31, 2016 | 44.82% |
| Dec 31, 2015 | -3.85% |
| Sep 30, 2015 | 57.65% |
| Jun 30, 2015 | 28.60% |
| Mar 31, 2015 | 54.50% |
| Dec 31, 2014 | 49.56% |
| Sep 30, 2014 | 7.18% |
| Jun 30, 2014 | -53.28% |
| Mar 31, 2014 | 14.55% |
| Dec 31, 2013 | 50.70% |
| Sep 30, 2013 | -20.72% |
| Jun 30, 2013 | 8.45% |